| INTRODUCTION
Irritable bowel syndrome (IBS) is a functional bowel disorder with a relapsing and remitting natural history. [1] [2] [3] The global prevalence of the condition in the community is approximately 10%, depending on the criteria used to define its presence, 4 although using the latest Rome IV criteria it is lower, estimated at 6%. 5 Despite being common, only a minority of people who report symptoms suggestive of IBS will consult a physician. 3 Because the pathophysiology of the disorder remains incompletely understood, medical treatment is empirical and is usually based on targeting the predominant symptom reported by the patient. 6 This leads to unsatisfactory control of symptoms for many patients and, therefore, alternative approaches are needed.
The concept that alterations in the gut microbiome might be relevant to IBS arose from observations that symptoms of IBS often developed after an infection, known as post-infectious IBS. 7, 8 Furthermore, small intestinal bacterial overgrowth (SIBO) may cause symptoms indistinguishable from IBS, 9 and data suggest that the colonic microbiome is altered in patients with IBS, when compared with healthy controls. [10] [11] [12] [13] In addition, some IBS symptoms, such as bloating, slowed gastrointestinal (GI) transit, and early satiety have been associated with specific gut microbiome profiles. 14, 15 Data from studies such as these suggest that alterations in the gut microbiome may induce IBS symptoms de novo or exacerbate existing symptoms. This then raises the obvious question of whether antibiotics, or other related interventions, can be used to modulate the gut microbiome and thus improve IBS symptoms. Prebiotics are substrates that are selectively utilised by host microorganisms, conferring a health benefit. 16 Probiotics have been defined as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host". 17 Synbiotics, which are also food or dietary supplements, are a mixture of probiotics and prebiotics that act synergistically to promote the growth and survival of beneficial organisms.
The use of antibiotics as a means of treating SIBO, a postulated pathophysiologic mechanism for IBS, remains an area of continuing controversy. This is because the tests commonly used to diagnose SIBO, such as lactulose and glucose hydrogen breath tests and small intestinal aspirates, are fraught with problems such as altered intestinal transit, [18] [19] [20] which influence their sensitivity and specificity.
Despite the fact that any effect of probiotics in IBS is poorly understood, a recent survey of clinicians demonstrated that most believe probiotics to be a benign therapy and over 90% incorporated probiotics into their clinical practice. 21 Gaining a better understanding of probiotics and their clinical use in IBS remains a challenging task due to variations in study design, strain, species and dose of probiotics as well as small size of study populations.
Previous systematic reviews by our group, 22, 23 conducted to inform the American College of Gastroenterology's (ACG) monograph on the management of IBS, 24, 25 have examined the role of prebiotics, probiotics and synbiotics, but not antibiotics, in IBS. In the intervening 4 years since our last meta-analysis, there have been further studies published. We therefore performed an updated systematic review and meta-analysis to examine the efficacy of prebiotics, probiotics, synbiotics and antibiotics in IBS.
| MATERIALS AND METHODS

| Search strategy and study selection
We updated our previous systematic review and meta-analysis examining the efficacy of prebiotics, probiotics and synbiotics in IBS, 23 searching the medical literature using MEDLINE (1946 to July 2017), EMBASE and EMBASE Classic (1947 to July 2017), and the Cochrane Central Register of Controlled Trials. Randomised placebocontrolled trials examining the effect of at least 7 days of prebiotics, probiotics, synbiotics or antibiotics in adult patients (over the age of 16 years) with IBS were eligible for inclusion (Table 1) , including the first period of cross-over RCTs, prior to cross-over to the second treatment. The diagnosis of IBS could be based on either a physician's opinion or symptom-based diagnostic criteria, supplemented
by the results of investigations to exclude organic disease, where studies deemed this necessary.
Subjects were required to be followed up for at least 1 week, and studies had to report response to therapy as either a dichotomous endpoint or via continuous data. Dichotomous assessment could be in the form of either an assessment of global symptom cure or improvement, or abdominal pain cure or improvement, after completion of therapy. Preferably, this information was reported by the patient, but if this was not recorded then data either as documented by the investigator or via questionnaire were accepted. Continuous data of interest were the effect of therapy on global and individual IBS symptom scores at study end. Where studies did not report these types of dichotomous or continuous data, but were otherwise eligible for inclusion in the systematic review, we attempted to contact the original investigators in order to obtain further information.
T A B L E 1 Eligibility criteria
Randomised controlled trials
Adults (participants aged >16 years) 
| Outcome assessment
The primary outcomes assessed were the effects of prebiotics, probiotics, synbiotics or antibiotics compared with placebo on global IBS symptoms or abdominal pain after cessation of therapy. Secondary outcomes included their effects on global IBS symptom scores and individual IBS symptom scores at study end, including abdominal pain, bloating, urgency or flatulence. We also examined numbers of adverse events as a result of prebiotics, probiotics, synbiotics or antibiotics.
| Data extraction
Two reviewers extracted all data independently on to a Microsoft 
| Assessment of risk of bias
Two reviewers assessed the risk of bias of each study independently, with disagreements resolved by consensus. Risk of bias was assessed as described in the Cochrane handbook, 27 by recording the method used to generate the randomisation schedule and conceal allocation, whether blinding was implemented for participants, personnel and outcomes assessment, whether there was evidence of incomplete outcomes data and whether there was evidence of selective reporting of outcomes.
| Data synthesis and statistical analysis
Data were pooled using a random effects model, 28 to give a more with RRs. The number needed to treat (NNT) and the number needed to harm (NNH), with 95% CIs, were calculated using the formula NNT or NNH = 1/(control event rate × (1 − RR)).
Heterogeneity, which is variation between individual study results that has not occurred due to chance, was assessed using both the I 2 statistic with a cut-off of ≥50%, and the chi-squared test with a P < 0.10, used to define a significant degree of heterogeneity. 29 Review Manager version 5. 
| RESULTS
The search strategy generated a total of 4017 citations, of which 111 published articles appeared to be relevant, and were retrieved for further assessment (Figure 1 The second recruited 79 patients with Rome III defined IBS, and randomised them to a 2.5 g sachet of either short-chain fructooligosaccharides or placebo for 4 weeks. 51 This trial was doubleblind, but was at unclear risk of bias, as the method used to conceal treatment allocation was not reported. Mean global symptom scores improved in both groups, compared with baseline, but there was no difference in the mean change in global symptoms scores between treatment arms (−122.3 with short-chain fructooligosaccharide vs −38.1 with placebo, P = 0.13) which, given the magnitude of the difference, is likely due to the trial being underpowered for this endpoint. Again, adverse events rates in each arm were similar.
The third study was a cross-over trial and recruited 60 patients with Rome II-defined IBS. 52 All participants were randomised to placebo for 4 weeks and then, following a washout period of 2 weeks, were re-randomised to 4 weeks of low-dose prebiotic (3.5 g of trans-galactooligosaccharide), high-dose prebiotic (7 g of trans-galactooligosaccharide), or placebo. This study was at unclear risk of bias as the method of randomisation was stated, but not the method of concealment of allocation, and only patients were blinded to treatment allocation. After the second 4 weeks of treatment, patients in both the low-and high-dose prebiotic arms experienced a significant reduction in mean global symptom scores, compared with those at the end of the 2-week washout, but there was no effect on mean abdominal pain scores. Adverse events were similar between all three treatment arms.
| Efficacy and safety of probiotics in IBS
The 53 RCTs of probiotics in IBS involved 5545 patients.
32-49,53-87
The proportion of women in trials ranged between 9% and 100%.
Twenty-six trials were at low risk of bias, Lactobacillus was used in eight trials (893 patients), 44, 48, 54, 55, 68, [82] [83] [84] with no clear benefit detected over placebo (RR = 0.82; 95% CI 0.63-1.06), again with significant heterogeneity between studies (I 2 = 83%, P < 0.001). However, when only the three RCTs that used Lactobacillus plantarum DSM 9843 were considered in the analysis, 54, 55, 83 which contained 314 subjects, the RR of symptoms persisting was Excluded (n = 45) because: • Combination probiotics = 29
• Lactobacillus = 11
• Bifidobacterium or Lactobacillus = 1
• Streptococcus = 1 Synbiotics (n = 2) Antibiotics (n = 8)
• Rifaximin (n = 6)
• Neomycin (n = 1)
Excluded (title and abstract confirmed not appropriate) (n = 3906) but not with any of the other probiotics studied.
Finally, eight RCTs reported the effect of probiotics on urgency symptom scores in 733 patients. 33, 39, 56, 58, 63, 75, 76, 80 There was no apparent benefit detected for any probiotic, in terms of effect on symptoms of urgency.
| Adverse events with probiotics
Total adverse events were reported by 36 RCTs, IBS-M. This double-blind trial was at unclear risk of bias due to failure in reporting the method used to conceal treatment allocation.
| Efficacy and safety of synbiotics in IBS
Only one trial reported dichotomous data, 88 and there were seven 
| Efficacy and safety of antibiotics in IBS
We identified nine trials, reported in eight separate papers, [90] [91] [92] [93] [94] [95] [96] [97] which evaluated antibiotic therapy in 2845 patients with IBS (Figure 6 ). Detailed trial characteristics are provided in Table 3 . One trial evaluated neomycin in 111 patients, 93 There remained a significant effect in favour of active therapy when only these RCTs were considered in the analysis (RR = 0.87; 95% CI 0.82-0.93) with no significant heterogeneity (I 2 = 0%, P = 0.81) and a NNT of 11 (95% CI 8-21).
| Adverse events with antibiotics
One paper pooled adverse events from two RCTs, meaning that these data were not extractable. 97 As a result, only three RCTs reported adverse events in 817 patients. 91, 93, 94 However, one of the RCTs reported no adverse events, 94 and one reported a single adverse event in the placebo arm, 93 meaning there were insufficient data to pool. A post hoc pooled analysis from the phase 2b and phase 3 rifaximin RCTs revealed no difference in adverse events (52% in both rifaximin and placebo arms) or serious adverse events (approximately 1.5% and 2.2% in each arm) between rifaximin and placebo. 98 There has been concern surrounding the risk of developing Clostridium difficile infection with antibiotics for IBS. A pooled analysis of the phase 2b study and two of the phase 3 studies found C. difficile in one patient at study entry who subsequently was removed from the study 98 . There was a zero incidence of C. difficile colitis that was developed de novo. In the TARGET 3 trial, a further case of C. difficile colitis was reported among the 328 patients randomised to re-treatment with rifaximin 91 . In terms of individual probiotics, Lactobacillus plantarum DSM 9843, E. coli DSM1752 and Streptococcus faecium, also appeared beneficial, although the latter two were only used in one RCT each. There was also a trend towards a beneficial effect of Bifidobacterium, in terms of improvement of global IBS symptoms and pain scores, although which particular strain or species may be of benefit remains unclear.
The largest trial was a dose-ranging study of Bifidobacterium infantis 35 624, and demonstrated efficacy, in terms of global symptoms and abdominal pain, at a dose of 1 × 10 8 CFU. 63 Overall, rifaximin was also superior to placebo for the treatment of nonconstipated IBS, with a NNT of 9. There was only one trial each of norfloxacin and neomycin, making it difficult to draw any firm conclusions regarding their efficacy. The RR of adverse events was not significantly greater with either probiotics or antibiotics. Data for both prebiotics and synbiotics were sparse, with neither appearing to be of particular benefit in IBS, albeit in only five trials in total.
We used rigorous and reproducible methodology when conducting this systematic review and meta-analysis. We reported our search strategy in full, and performed the assessment of eligibility and data extraction independently, and in duplicate. We used an intention-to-treat analysis and pooled data with a random effects model, to minimise the likelihood that treatment effect would be overestimated. We also contacted investigators of potentially eligible studies to either obtain dichotomous data and continuous data. This inclusive approach has provided us with access to data for >5500 IBS patients treated with probiotics. Finally, we performed subgroup analyses in an attempt to assess treatment effect according to combinations of, and individual, probiotics used and we extracted and pooled adverse events data, where reported.
This updated meta-analysis identified a further 18 RCTs of probiotics and three trials of prebiotics since the previous iteration 4 years ago, but it is still not possible to draw clear inferences from the data concerning the efficacy and safety of either prebiotics or synbiotics. For probiotics, it remains unclear whether a particular combination of probiotics, or a specific species or strain, is more likely to be effective, or whether there is a particular IBS subtype that is more likely to benefit. Other limitations of this systematic (2013) Whorwell (2006) Choi (2011) Nobaek (2000) The rationale for the use of antibiotics in patients with IBS was based on diagnostic confusion between IBS and SIBO, with patients in the initial studies undergoing hydrogen breath testing to confirm the presence of SIBO prior to enrolment. 93, 99 However, in the pivotal RCTs of rifaximin breath testing was only undertaken in a subset of individuals, and the results were not reported in full. 91, 97 In addition, the mechanism of action of rifaximin in IBS remains unclear. A small mechanistic trial found no difference in terms of the faecal microbiome, intestinal permeability or faecal bile acid levels humans. 103, 104 In addition, in one of the trials we identified, Bifidobacterium infantis 35 624 had the ability to normalise interleukin levels in patients with IBS. 60 More recently, the probiotic Bifidobacterium longum NCC3001 has been demonstrated to have a beneficial effect on depression scores among patients with IBS in a RCT. 47 Brain activation to fearful stimuli, seen on functional magnetic resonance imaging, was also reduced among patients allocated to the probiotic in this study. Interestingly, both this effect and the improvement in depression scores appeared to be most pronounced among those with adequate relief of their IBS symptoms. However, it is unlikely that these are class effects of probiotics, and further research in humans is required to identify species and strains of probiotics that are consistently beneficial, as well as to elucidate how these benefits are achieved. 
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